Exenatide for weight-loss maintenance in adolescents with severe obesity: A randomized, placebo-controlled trial

What Was Tested

This randomized controlled trial paper looks at Exenatide in the context of fat loss, obesity & body recomposition.

Who Took Part

The abstract describes 100 participants taking part.

PubMed indexes the participants as teenagers, both men and women.

In this randomized, double-blind, placebo-controlled trial, 100 participants aged 12 to 18 years with BMI ≥ 1.2 × 95th percentile were enrolled in a short-term MRT run-in phase.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Exenatide, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Exenatide group a baseline to be compared against.

Both groups also received lifestyle therapy.

The prespecified primary end point was mean percent change in BMI from randomization (post run-in) to 52 weeks in the intention-to-treat population.

What Was Measured

PubMed files the paper under topics including Exenatide, Hypoglycemic Agents, Obesity, Morbid and Weight Loss.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide in 100 participants in people with fat loss, obesity & body recomposition.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (Obesity (Silver Spring, Md.)), a journal based in United States.

More context: the Exenatide compound page, Fat loss, obesity & body recomposition research.